TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03394196

RESIST-2: 2nd-line ART for HIV-2 Infection

Cause of deathStaffing, sites or logistics, also funding or business Automatic label, confidence 0.5, unverified. How labels are made.
“COVID-19 and Funding”

The sponsor’s own words in the registry.

Life of this trial

20172018201920202021Registered2017-12-14Started2018-07-04Stopped2020-05-31

Vital statistics

Status
Terminated
Phase
Na
Sponsor
University of Washington
Sponsor type
University, hospital or other
Conditions
HIV-2 Infection
Interventions
HIV-2 Genotypic Drug Resistance Testing using DBS; 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID); 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ); 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)
Participants
152
Sites
2
Countries
Senegal

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.